Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP + 90Y-Ibritumomab Tiuxetan in Untreated MCL
NCT00070447Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2003
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Started Nov 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00070447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070447.